Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Both Ford and Pfizer have very attractive dividend yields.

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on the bearish thesis of PFE stock.

Pfizer’s PFE second-quarter 10% revenue growth and adjusted EPS of $0.78 were ahead of consensus expectations. Management maintained full-year revenue guidance of $61 billion-$64 billion and raised ...

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share placement, the company said in a Hong Kong Stock Exchange filing after the close ...

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized ...

Shanghai Fosun Pharmaceutical is one of China's largest pharmaceutical companies. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) In its latest agreement with a China ...

Roughly two blocks from Manhattan’s Grand Central Terminal, construction workers are stripping down the former Pfizer Inc. headquarters to its columns, beams and concrete slabs. The office towers are ...